Brokerages Set MiNK Therapeutics, Inc. (NASDAQ:INKT) Target Price at $35.00

MiNK Therapeutics, Inc. (NASDAQ:INKT) has earned an average recommendation of “Hold” from the five research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $35.00.

Separately, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 19th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC lifted its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the quarter. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Trading Up 1.6%

INKT stock opened at $11.37 on Friday. The firm has a 50-day moving average of $11.75 and a two-hundred day moving average of $13.05. MiNK Therapeutics has a 12 month low of $6.34 and a 12 month high of $76.00. The company has a market cap of $53.33 million, a price-to-earnings ratio of -3.75 and a beta of 0.34.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.